Navigation Links
Global menopause summit concludes HRT is safe for healthy women entering menopause
Date:5/19/2008

Global menopause summit concludes HRT is safe for healthy women entering the menopause.

HRT in the early postmenopausal period is safe, and healthy women going through the first few years of the menopause who need HRT to relieve symptoms should have no fears about its use. This is the conclusion and clinical advice of the First Global Summit on Menopause-Related Issues, which was held in Zrich on March 29th and 30th, 2008.

The Zrich Summit was attended by global experts in menopause and related issues. It reviewed the evidence on the safety, risks and benefits of HRT in the first few years of the menopause, looking at 4 main areas of controversy: cardiovascular health, breast issues, cognition, and bone issues. Summit members compared public perception with actual safety, and are now issuing a state-of-the science summary, to enable women and clinicians to make informed judgements about whether or not to use HRT in early menopause.

Professor Amos Pines, President of the International Menopause Society, will present the Summit findings at the World Congress on the Menopause in Madrid on 20th May.

Background the WHI Study

Hormone replacement therapy (HRT) use declined after the Womens Health Initiative (WHI) study results were published in 2002. Initial results from the WHI study seemed to show that women taking HRT were at greater risk of breast cancer and heart disease, and this study had a dramatic effect on public perceptions and confidence in the use of HRT. However, since the first WHI information was released, it has become apparent that the study group was not completely representative of women taking HRT, and was characterized by a high incidence of several important risk factors, unusual in younger women around their menopause. For example:

  • The average age of women in the WHI study was 63 years of age, which is a decade older than the age at which most women begin taking HRT

  • Of women randomly assigned in the WHI study, 36% had hypertension, 49% were current or past smokers, and 34% were clinically obese, which are all factors which would contribute to increased health problems.

In addition, the reporting of the study did not make clear that different HRTs have different risks and benefits, but most importantly the most recent reports from WHI have clearly shown that the age at which HRT is started is critical. Most experts now agree that the fall-out from the initial WHI results has led to public concern about HRT use, which is not justified by the clinical evidence.

The Zrich Summit

The Zrich Summit was called to review the current evidence, and to review the risks and benefits of using HRT for women in early menopause. Forty of the worlds leading menopause experts met to review public perceptions, risks and benefits. Their main conclusions were:

Cardiovascular issues

Combined oestrogen and progesterone do not increase chronic heart disease risk in healthy women aged 50-59; oestrogen alone actually decreases risk in this group.

Breast cancer

Certain types of HRT (combined oestrogen and progesterone) can lead to a slightly increased risk of breast cancer. However, this is minimal in relation to other breast cancer risk factors. Women with no prior use of estrogen alone actually had no increased risk for breast cancer in the WHI. Short-to-medium term use of oestrogen-only HRT does not show this effect. The key message is that each woman should discuss her general health, and risk factors such as a family history, smoking, etc., with her own doctor, but generally healthy women (i.e. with no other breast cancer risk factors) entering the menopause should have no fears.

Bone

HRT is effective in maintaining bone health in 50 to 59-year-old postmenopausal women.

Cognition

HRT does not impair cognition in healthy women aged 50-59, and may even delay the decrease of cognitive functions in this group.

Presenting the data at the Madrid Menopause congress, International Menopause Society President Professor Amos Pines (Tel-Aviv, Israel) said:

This is positive news about HRT in the early menopause years, between the ages of 50 and 59. The Zrich Summit is the most important menopause workshop to discuss this issue, and it would be hard to find a more distinguished group of experts in the field. Their conclusions are that, for most women entering the menopause, HRT is a good and safe option. Of course, each woman is an individual, and HRT use should be decided after discussions with her doctor.

Dr Roger Lobo (Columbia University, New York), who was one of the US clinicians attending the Zurich Summit, said

Each woman is an individual, and its important that she comes to an agreement with her doctor about using HRT. But the take-home message from this important summit is that for young healthy women at the onset of menopause, there is very little risk and the benefits outweigh the risks for women with symptoms.

The work of this international summit reinforces the findings of other bodies working in the field. As new data has emerged over the last few years, and as the original data has been re-examined, several bodies in the US, such as the American Association of Clinical Endocrinologists, and the North American Menopause Society, have also come to similar conclusions. This summit provides the global agreement on these views.


'/>"/>

Contact: Tom Parkhill
trparkhll@yahoo.co.uk
44-750-921-5465
International Menopause Society
Source:Eurekalert

Related medicine news :

1. Zimmer Holdings Names Mark C. Throdahl Group President, Global Businesses
2. Chiltern Expands Its Global Reach to Latin America
3. Response Biomedical Corporation to Present at Rodman & Renshaw 5th Annual Global Healthcare Conference
4. Global Pharmaceutical Launches: Best Practices for Winning Product Launch Successes
5. Haemacure announces webcast of presentation at Rodman & Renshaw 5th Annual Global Healthcare Conference
6. Anesiva Announces May 22, 2008 Presentation at Citi Investment Research Global HealthCare Conference
7. MEDEX Global Group Acquires ASI Group
8. BELLUS Health to present at the Rodman and Renshaw 5th Annual Global Healthcare Conference
9. Cynosure to Present at 2008 Citi Investment Research Global Health Care Conference
10. Alexzas Corporate Presentation to be Webcast at the Seventh Annual JMP Securities Research Conference and the 2008 Citi Investment Research Global Healthcare Conference
11. AUA 2008: Global warming may lead to increase in kidney stones disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, the Health ... Miles by Moonlight to raise money for the American Heart Association Heart Walk. Teams ... Teams will work together to keep their treadmills moving for 5 hours. Treadmills will ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... first interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), ... patient education, today announce a new strategic alliance. , As CPEN’s strategic ...
(Date:10/12/2017)... Miramar, FL (PRWEB) , ... October 12, 2017 ... ... is presenting the latest in wound care advancements to physician colleagues, skilled nursing ... lecture is titled, "Navigating the Treacherous Waters of Wound Care." , "At many ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... 12, 2017   Divoti USA will engrave ... the standard of the latest FDA requirements, which stipulates new criteria ... Anyone in need of Medical ID jewelry such as Medical ID ... are engraved in terms of the new FDA requirements . ... Divoti offers this dark mark ...
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
(Date:10/7/2017)... Oct. 6, 2017   Provista, a proven ... $100 billion in purchasing power, today announced a new ... The Newsroom is the online home for ... infographics, expert bios, news releases, slideshows and events. ... a wealth of resources at their fingertips, viewers can ...
Breaking Medicine Technology: